Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia

Figure 2

Reported general side effects and toxicities associated with TCH (docetaxel, carboplatin, and trastuzumab) versus TCHP (docetaxel, carboplatin, trastuzumab, and pertuzumab). The most common toxicities documented in the patient records by severity are shown. Numbers indicate percentages of patients with documented evidence of specific adverse toxicities. The severity of side effects was established according to Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0, June 2010, National Institutes of Health, National Cancer Institute [6]. Mild side effects were classed as CTCAE grade 1, moderate as CTCAE grades 2-3, and severe as CTCAE grade 4 side effects.